Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

How Much Health Care For $1 Trillion?
USA Today asks what the additional $1 trillion cost of a health care overhaul (over 10 years) will actually buy. "Although the eye-popping price tag would help boost insurance coverage to 95% or more of the public, it"s not enough to do everything advocates initially want. The proposals being shaped in Congress - including the $1.042 trillion bill unveiled by House Democratic leaders Tuesday - offer subsidies to fewer moderate-income families than originally intended, bar most workers from choosing to leave their employer-provided plans and likely drive up Medicaid costs for states." The Congressional Budget Office estimates that "at the end of a decade, 15 million to 20 million would remain uninsured."
generic viagra online
New Report: Private And Public Insurance Choices Would Help Reduce Administrative Health Care Costs By $265 Billion Over 10 Years
As lawmakers debate how to pay for an overhaul of the nation"s health care system, a new report from The Commonwealth Fund projects that including both private and public insurance choices in a new insurance exchange would save the United States as much as $265 billion in administrative costs from 2010 to 2020. Congressional leaders are attempting to keep 10-year federal budget costs of health care reform legislation under $1 trillion.
News of the day
Cobalis Corporation Is Awarded Two New International Patents In Canada And Mexico For Its Revolutionary Anti-Allergy Relief Product PreHistin(R)
Cobalis Corporation (OTC:CLSC) was recently awarded two additional International Patents in Canada and Mexico and has a patent pending application in Japan. PreHistin® is patented, safe for long-term daily use and available without a prescription. It is available in a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers" response to both indoor and outdoor allergens with daily and year round usage.
Endocrinology

CytRx's INNO-206 Demonstrates Statistically Significant Tumor Shrinkage In Animal Trial For Breast Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that its investigational cancer drug INNO-206 caused a dramatic destruction of implanted tumors in an experimental animal model of breast cancer, performing considerably better than the broadly used and generally effective chemotherapeutic drug doxorubicin. In addition to improved efficacy in this animal trial, INNO-206 was comparable in toxicity with doxorubicin based on animal body-weight loss. CytRx has exclusive worldwide rights to INNO-206, a proprietary derivative of doxorubicin. The pro-drug INNO-206 is designed to allow controlled release of doxorubicin and to specifically target the delivery of drug to tumors throughout the body, which could prove more effective and less toxic in cancer patients than doxorubicin. INNO-206 has previously demonstrated safety and tolerability, and optimal dosing has been evaluated, in a Phase I clinical trial. In the animal trial - conducted under the direction of INNO-206 inventor Felix Kratz, Ph.D., Department of Medical Oncology, Clinical Research, at the Tumor Biology Center in Freiburg, Germany - human breast tumor cells were implanted in mice with compromised immune systems to avoid tumor rejection. Seven to eight animals were randomly assigned into each of three experimental groups receiving intravenous injections with either a maximum tolerated dose of INNO-206, a maximum tolerated dose of doxorubicin, or a control solution lacking either compound. At the end of the experiment 43 days after implantation, tumors had increased in volume by an average of approximately 2.7-fold in the control group while tumor growth was marginally inhibited in the doxorubicin group; increasing in volume by approximately 1.9-fold in a result that did not reach statistical significance. By contrast, tumors in the group treated with INNO-206 shrank to approximately one-half their initial volume. The decrease in final tumor volume in INNO-206-treated animals was statistically significant (pAbout Breast Cancer Breast cancer is the most common cancer among women in the U.S., with more than 192,000 new cases of invasive breast cancer expected to be diagnosed this year, according to American Cancer Society estimates. More than 40,000 deaths are expected to be attributed to breast cancer in the U.S. in 2009, making it the second leading cause of cancer death in U.S. women. The chance of a woman having invasive breast cancer some time during her life is about one in eight. About INNO-206 INNO-206 is a prodrug of the commonly prescribed chemotherapeutic doxorubicin and was designed to reduce adverse events by controlling release and preferentially targeting the tumor. In a Phase 1 study, doses were administered at up to six times the standard dosing of doxorubicin without an increase in observed side effects over those historically seen with doxorubicin. The Company is evaluating options for a possible Phase 2 clinical trial. CytRx Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009